Survival
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
Journal for Immunotherapy of Cancer 2021 October [Link] Yosuke Miyamoto, Toshiyuki Kozuki, Keisuke Aoe, Sae Wada, Daijiro Harada, Michihiro Yoshida, Jun Sakurai, Katsuyuki Hotta, Nobukazu Fujimoto Abstract Background: JME-001 is a phase II trial assessing the efficacy and safety of cisplatin, pemetrexed, and nivolumab as first-line therapy in malignant pleural mesothelioma (MPM). Patients and methods:…
Read MoreNon-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study
Annals of Surgical Oncology 2021 October 28 [Link] Vahan Kepenekian, Julien Péron, Benoit You, Isabelle Bonnefoy, Laurent Villeneuve, Mohammad Alyami, Naoual Bakrin, Pascal Rousset, Nazim Benzerdjeb, Olivier Glehen Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive primary peritoneal neoplasia. At diagnosis, few patients are eligible for a recommended cytoreductive surgery (CRS) and hyperthermic…
Read MorePrediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion
Thoracic Cancer 2021 October 26 [Link] Shu Zhang, Yuan Zhang, Wei Feng, Zhongyue Shi, Huanzhong Shi, Yuhui Zhang Abstract Background: Malignant pleural effusion (MPE) is common in malignant pleural mesothelioma (MPM). The survival of patients with MPM and MPE is heterogeneous. The LENT and BRIMS scores using routine clinical parameters were developed to predict the…
Read MoreTreatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data
Cancer Reports 2021 October 26 [Link] Mark D Danese, Melinda Daumont, Esmond Nwokeji, Michelle Gleeson, John R Penrod, Deborah Lubeck Abstract Background: Malignant mesothelioma is a rare neoplasm associated with asbestos exposure. Characterizing treatment patterns and outcomes of older patients with advanced malignant pleural mesothelioma (MPM) is important to understand the unmet needs of this…
Read MoreExtracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients
Journal of Personalized Medicine 2021 October 9 [Link] Katja Goričar, Marija Holcar, Nina Mavec, Viljem Kovač, Metka Lenassi, Vita Dolžan Abstract Malignant mesothelioma (MM) is characterized by poor prognosis and short survival. Extracellular vesicles (EVs) are membrane-bound particles released from cells into various body fluids, and their molecular composition reflects the characteristics of the origin…
Read MoreA 3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma
Frontiers in Oncology 2021 October 1 [Link] Fabrizio Vincenzi, John Charles Rotondo, Silvia Pasquini, Francesco Di Virgilio, Katia Varani, Mauro Tognon Abstract Human malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor of the serosal cavities whose 5-year survival rate is 15%. At present, there are no effective therapies for MPM. Although recent findings…
Read MorePhase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene
JTO Clinical and Research Reports 2021 September 17 [Link] Azam Ghafoor, Idrees Mian, Cathy Wagner, Yvonne Mallory, Maria Garcia Agra, Betsy Morrow, Jun S Wei, Javed Khan, Anish Thomas, Manjistha Sengupta, Seth M Steinberg, Raffit Hassan Abstract Introduction: PARP inhibition may enhance antitumor responses in BAP1-associated mesothelioma by inducing synthetic lethality. Methods: A single-center, nonrandomized,…
Read MoreThoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas
Thoracic Cancer 2021 October 15 [Link] Kanji Otsubo, Hiroki Sakai, Hiroyuki Kimura, Tomoyuki Miyazawa, Hideki Marushima, Koji Kojima, Naoki Furuya, Masamichi Mineshita, Motohiro Chosokabe, Junki Koike, Hisashi Saji Abstract Background: The current study aimed to evaluate the significance of clinicopathological factors, particularly the immunohistochemistry of programed cell death ligand-1 (PD-L1), in eight cases each of…
Read MoreMatrix Metalloproteinases as Biomarkers and Treatment Targets in Mesothelioma: A Systematic Review
Biomolecules 2021 August 25 [Link] Danijela Štrbac, Vita Dolžan Abstract Metalloproteinases (MMPs) have an important role in tissue remodeling and have been shown to have an effect on tumor progression, invasion, metastasis formation, and apoptosis in several tumors, including mesothelioma. Mesothelioma is a rare tumor arising from pleura and peritoneum and is frequently associated with…
Read MoreIntegrated genomics point to immune vulnerabilities in pleural mesothelioma
Scientific Reports 2021 September 27 [Link] Anca Nastase , Amit Mandal, Shir Kiong Lu, Hima Anbunathan, Deborah Morris-Rosendahl, Yu Zhi Zhang, Xiao-Ming Sun Spyridon Gennatas, Robert C Rintoul, Matthew Edwards, Alex Bowman, Tatyana Chernova, Tim Benepal, Eric Lim, Anthony Newman Taylor, Andrew G Nicholson, Sanjay Popat, Anne E Willis, Marion MacFarlane, Mark Lathrop, Anne M…
Read More